A purity statement aligned to LC MS measurement is included to support research documentation standards, and storage guidance specifies cold refrigerated conditions with avoidance of freezing to promote consistent handling across multi run timelines
Researchers also examined major adverse CV events in patient subgroups on the basis of major adverse CV event rates in the placebo group, the presence or absence of CVD, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age and eGFR
Clinical: 1.0% topical idebenone reduced roughness/dryness (26%), increased hydration (+37%), reduced fine lines (29%), and improved overall photodamage (+33%) in 6 weeks
While some providers may see microdosing as a way to ease patients into treatment or reduce side effects, others worry about its risks